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Evaluation of Oncology Nurses’ Knowledge, Practice Behaviors, and Confidence 
Specific to Chemotherapy Induced Peripheral Neuropathy 
 
R. Denise McAllister 
Abstract 
Chemotherapy induced peripheral neuropathy (CIPN) remains one of the most 
serious and challenging symptoms oncology nurses encounter in caring for patients 
receiving neurotoxic chemotherapy. CIPN is under-addressed, under-reported, and 
symptoms are minimized by healthcare providers, which adversely affect patient quality 
of life, physical function, and emotional well-being. There is an absence of research 
examining nurses’ knowledge and practice behaviors related to CIPN. The purpose of 
this study was to explore oncology nurses knowledge, practice behaviors, confidence, and 
the relationship between education, experience, and knowledge specific to CIPN. 
Data was collected at Oncology Nursing Society (ONS) Chapter meetings 
throughout central and south Florida. The sample consisted of 70 oncology nurses who 
provide direct care to patients with cancer. Participants completed the CIPN: Assessment 
of Oncology Nurses’ Knowledge and Practice–Revised questionnaire. Demographic data 
revealed the overall years of nursing experience mean to be 24.7 (SD=12.2), mean years 
of oncology experience to be 13.5 (SD=7.5), and mean age to be 50.3 years (SD=9.5). 
The participants varied in highest attained level of education with the majority having 
Bachelor of Science degrees (40.0%). 
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The results of this study revealed adequate nursing knowledge pertaining to CIPN 
13.0 (SD=1.9) (81%). Fifty-percent of nurses reported always or frequently screening for 
CIPN. The majority of participants reported always or frequently; evaluating fine motor 
skills (68.6%), documenting findings (64.3%), assessing risk factors (55.7%), assessing 
motor function (52.9%), performing assessment prior to each neurotoxic chemotherapy 
infusion (58.6%), eliciting patient symptoms (65.7%), teaching strategies for adaptation 
(57.1%), and teaching safety precautions (74.3%). Nurses less frequently reported always 
or frequently assessing deep tendon reflexes (17.2%) and assessing muscle strength 
(35.7%). The majority reported confidence in sharp vs. dull sensation testing (62.8%), 
and manual muscle strength testing (52.9%), while the majority lacked confidence 
performing deep tendon reflex testing (71.5%), tuning fork vibration sensation testing 
(72.8%), and Romberg testing (72.8%). There was a significant relationship between 
highest educational level achieved and knowledge of CIPN (r=.252, p=.037). 
This is one of two studies documenting oncology nurses’ knowledge, practice 
behaviors, and confidence specific to CIPN. Findings lay the foundation in documenting 
the need for providing oncology nurses with continued education, and the need to teach 
oncology nurses the skills necessary to confidently assess for CIPN and interpret the 
findings.
 v
  
Chapter I: Introduction 
The American Cancer Society (ACS) estimates 1,500,000 people are diagnosed 
with cancer annually with an estimated 11.1 million Americans living after a cancer 
diagnosis (ACS, 2009). Chemotherapy is an integral component of the cancer treatment 
paradigm that promotes cure, disease control, or palliation of symptoms. Chemotherapy-
induced peripheral neuropathy (CIPN) is a serious clinical problem that affects those 
receiving: platinum based compounds; taxanes; plant alkaloids; biologics; 
antiangiogenesis agents; and proteasome inhibitors used for treatment of a variety of solid 
and hematologic malignancies (Visovsky, Collins, Abbott, Aschenbrenner, & Hart, 2007; 
Wilkes, 2007). Despite advances in therapies and side effect management, CIPN remains 
one of the most challenging symptoms oncology nurses encounter in caring for patients 
receiving neurotoxic chemotherapy (Wilkes, 2007). 
Sensory signs and symptoms may include tingling, numbness, and burning in the 
hands and feet. Usually the symptoms are bilateral and are worse in the lower extremities. 
Symptoms may also include pain, and loss of vibratory, position, and temperature sense, 
touch, deep tendon reflexes, and two-point discrimination (Armstrong, Almadrones, & 
Gilbert, 2005). CIPN causes a disruption in work responsibilities and leisure activities 
with functional deficits based on location of paresthesias involving fingers, hands, arms, 
toes, feet, and legs (Bakitas, 2007). Functional effects of CIPN include but are not limited 
to; mobility and safety issues, weakness of extremities, inability to sense temperature 
changes, difficulty performing tasks that require hand and foot manipulation, and pain in 
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affected extremities (Bakitas, 2007; Tofthagen, 2010). Risk factors for CIPN include 
exposure to neurotoxic chemotherapy, concurrent use of neurotoxic medications, 
previous radiation to spinal fields causing pre-existing neuropathy, malignancies 
associated with pre-existing neuropathy such as multiple myeloma, co-morbid conditions 
such as diabetes mellitus, hypothyroidism, vitamin B deficiencies, human 
immunodeficiency virus, renal insufficiency, and alcoholism (Armstrong, et al., 2005; 
Wickham, 2006). 
CIPN is under-addressed, under-reported, and minimized by oncology healthcare 
providers causing patients to suffer the ill effects of chemotherapy induced peripheral 
neuropathy and lack of management (Smith, Beck, & Cohen, 2008). The experience of 
CIPN negatively influences patient’s daily lives, adversely affecting quality of life (QOL) 
and physical function of patients with cancer who receive neurotoxic chemotherapy 
agents (Bakitas, 2007; Tofthagen, 2010). In addition to compromising patients’ QOL, 
treatment dose reductions, treatment discontinuation, or treatment postponement can 
occur due to the dose-limiting toxicity of CIPN (Kuroi et al., 2008; Visovsky, et al., 
2007). 
Problem Statement 
There is an absence of research examining oncology nurses’ knowledge of 
pathophysiology of the peripheral nervous system, neurotoxic effects of chemotherapy, 
interventions used to manage CIPN, and the impact of CIPN to those receiving 
neurotoxic agents. Research is needed to examine nurse’s knowledge of this phenomenon 
because knowledge is pre-requisite to practice (Curley, 1998). Oncology nurse’s 
knowledge of CIPN needs to be assessed and any identified deficits need to be rectified 
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for the preservation of safety and improved QOL of oncology patients. The purpose of 
this study was to explore oncology nurses’ knowledge, practice behaviors, and 
confidence in assessing for CIPN. 
Research Questions 
The aim of this study was to answer the following research questions: 
1. What is the level of knowledge among oncology nurses regarding CIPN?  
2. What are oncology nurses’ self-reported practice behaviors in assessing for CIPN? 
3. How confident are oncology nurses in assessing CIPN in their patients? 
4. What is the relationship between oncology nurses experience, level of education, and 
knowledge specific to CIPN? 
Definitions of Terms 
For the purpose of this study, the following terms are defined: 
Peripheral nervous system: the portion of the nervous system that is outside the brain and 
spinal cord, that transmits information between the central nervous system (e.g. the brain 
and spinal cord) and the rest of the body (Sweeney, 2002).  
Chemotherapy induced peripheral neuropathy: neuromuscular systems due to damage to 
the peripheral nervous system, induced by neurotoxic chemotherapeutic agents 
(Visovsky, et al., 2007). 
Function: ability to perform activities related to personal care and role responsibility 
(Barsevick, Much, & Sweeney, 2000). 
Quality of life: patients’ self-assessment of and satisfaction with their current level of 
functioning compared to what is perceived to be possible or ideal (Cella, & Tulsky, 
1990). 
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Significance to Nursing 
Symptom management and improving QOL are the primary focus of oncology 
nursing. CIPN is an unpleasant symptom that can potentially adversely affect the QOL, 
function, and safety of patients with cancer. Nurses can advocate on behalf of patients by 
understanding the distressing influence and long-term sequella CIPN can have on daily 
living. It is estimated ten to one-hundred percent of patients with cancer will develop 
CIPN depending on drugs, dosages, existing co-morbid conditions, and measurement tool 
utilized by the healthcare team (Bakitas, 2007). Nurses being in the forefront of oncology 
care are in the best position to identify neurotoxic agents, educate patients on early 
symptoms, assess for symptoms, and anticipate the care the patient will require with the 
intent to minimize or alleviate the burden of CIPN. Nurses have a great opportunity to 
evaluate their own knowledge of CIPN regarding assessment and intervention strategies 
relevant to clinical practice for the preservation of safety and improved QOL of the 
oncology patient. This study may shed light on oncology nurses’ level of knowledge, 
practice behaviors, confidence in neurological assessment pertaining to CIPN, and the 
relationship between knowledge of CIPN, and level of education, and nursing experience. 
The results of this study will be applied to the creation of a larger intervention study 
aimed at the management of CIPN. In addition, data generated from this study will help 
direct educational programs for oncology nurses. 
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Chapter II: Review of the Literature 
This chapter outlines the review of literature. The theoretical framework is 
presented first, followed by pathophysiology, impact of CIPN on function and QOL, 
measurement tools, prevention and treatment strategies, and a summarization of the 
literature.  
Theoretical Framework 
The Synergy Model for Patient Care developed by the American Association for 
Critical Care Nursing provides the conceptual framework for this research. The premise 
of the Synergy Model for Patient Care, is when patient characteristics and nurses 
competencies match, optimal patient outcomes are achieved (Curley, 1998).The model 
identifies eight common characteristics displayed by patients when confronted with a 
health issue. These include resiliency, vulnerability, stability, complexity, resource 
availability, participating in care, participating in decision-making, and predictability. 
These characteristics aid the nurse in anticipating the needs of patients and providing 
optimal care based on the patient’s unique needs. The identified nursing characteristics 
include clinical judgment, advocacy-moral agency, caring practices, collaboration, 
systems thinking, response to dignity, clinical inquiry, and facilitator of learning 
(Arashin, 2010; Curley, 1998). The Synergy Model can be incorporated to guide clinical 
practice with CIPN as the primary focus. CIPN can place patients in a vulnerable state 
with possible compromise to treatment outcomes and can induce physiological or 
psychological stress. Nurses can identify a predictive path based on disease, risk factors, 
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selection of neurotoxic agents, and noting how patients are responding to neurotoxic 
chemotherapy. Oncology nurses can apply their clinical expertise, provide compassionate 
care, advocate on behalf of patients, and collaborate with interdisciplinary team members 
when approaching the care of patients with CIPN to minimize or alleviate the burden of 
CIPN.  
Pathophysiology of CIPN 
The nervous system is comprised of the central nervous system (CNS) and 
peripheral nervous system (PNS). The PNS consist of sensory, motor, and autonomic 
nerves. The sensory nerve fibers transmit impulses from the periphery to the CNS. The 
motor nerve fibers transmit impulses from the CNS to the muscles or organs. The large 
myelinated sensory nerves control vibration and position sense and unmyelinated small 
fiber sensory nerves control pain, perception of touch, and temperature. Motor nerves 
control voluntary movement, coordination, and maintain muscle tone. The autonomic 
peripheral nerves control blood pressure, intestinal motility, and involuntary muscles 
(Armstrong, et al., 2005; Wilkes, 2007). 
The underlying pathophysiology rationale for developing CIPN has not been fully 
described, because of incomplete understanding. The pathogenesis may vary depending 
on the neurotoxic agent administered. Neurotoxic chemotherapeutic agents are thought to 
damage sensory axons, leading to degeneration and dying back of axons and myelin 
sheaths. Axons can regenerate, however, damage to cell bodies is often not reversible 
(Wickham, 2006). 
Patients commonly speak of severe symptoms of CIPN causing interference with 
physical function including the inability to button clothing, write, drive, or walk (Bakitas, 
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2007; Tofthagen, 2010). Sensory signs and symptoms include numbness, tingling, 
burning, pain, ataxia, loss of deep tendon reflexes, and reduced sense of touch, vibration, 
and proprioception. Motor symptoms include weakness, gait disturbances, balance 
disturbances, and difficulty with fine motor skills. Autonomic symptoms include 
constipation, urinary retention, sexual dysfunction, and altered blood pressure (Bakitas, 
2007; Visovsky, et al., 2007; Wilkes, 2007). These CIPN symptoms may be acute, mild 
or severe, transient, or prolonged (Postma, & Heimans, 2000). 
Symptoms of CIPN are related to the affected nerve fibers. Sensory changes are 
usually noted first in the toes and feet, the fingers and hands second, followed by a 
proximal progression to the ankles and wrist in a stocking glove-manner (Wolf, Barton, 
Kottschade, Gothey, & Loprinzi, 2008). The distribution of symptoms is bilateral and 
symmetrical. Symptoms of CIPN can become progressively worse after discontinuing the 
neurotoxic agent. This phenomenon is known as coasting and occurs as result of 
receiving a cumulative amount of drug. The onset is usually a gradual progression; 
however, rapid onset can occur after receiving a neurotoxic agent (Wilkes, 2007). 
Patients with pre-existing conditions, such as diabetes mellitus, alcohol related peripheral 
neuropathy, ischemic disease, vitamin deficiencies, renal insufficiency, prior exposure, or 
concurrent use of neurotoxic agents could be at increased risk for CIPN (Armstrong, et 
al., 2005; Wilkes, 2007). 
Peripheral neuropathy may be reversible with dose modification or 
discontinuation, and in some cases; the damage is irreversible. The incidence and type of 
CIPN is dependant on the causative drug (Table 1) (Wilkes, 2007).  
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Table 1 
CIPN: Causative Agent, Incidence, and Type 
Agent Incidence Type 
Carboplatin                13%-42% Sensory progressing to mixed sensori-motor 
Cisplatin 57%-92% Sensory progressing to mixed sensori-
motor, autonomic 
Oxaliplatin 13%-92%  Sensory, autonomic 
Paclitaxel 59%-78%  Mixed sensori-motor 
Docetaxol 20%-58% Sensori-motor 
Vincristine 57% Mixed sensori-motor, autonomic 
Vinorelbine 7%-31% Motor and autonomic 
Bortezomib 35% Sensory, mixed sensori-motor 
Thalidomide 22%-54% Sensori-motor 
Note. Adopted from Wilkes (2007). 
Impact on Function and QOL 
Symptoms of CIPN, other than numbness and tingling in the hands and feet have 
gained little attention in the literature. Bakitas (2007) purposely recruited 28 participants 
from a rural National Cancer Institute designated comprehensive cancer center to this 
qualitative study to better understand the impact of CIPN on daily living and function. 
The eligibility criteria included patients identified as having numbness, tingling, burning, 
shock-like, or painful sensations present bilaterally in feet or hands that was not present 
prior to initiation of chemotherapy, and found to be related to the initiation of 
chemotherapy. Demographics of participants included; mean age 59 years +/- 9.6 with an 
age range of 46-81 years, 71% female, median time since diagnosis was 34 months with 
range of 3-198 months, 50% had breast cancer, 21% had hematologic malignancies, 11% 
had ovarian cancer, 11% had colon cancer and 7% other malignancies. Primary data 
collection occurred through individual 25-90 minute interviews, which were audiotaped 
and transcribed into more than 700 pages of text. Data was analyzed using content 
analysis and constant comparison.  
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In this, qualitative study by Bakitas (2007), CIPN was best described as a constant 
drone that was distracting and unpleasant like that of background noise. Four themes that 
further defined the CIPN experience were becoming aware, learning new lyrics, 
functional, emotional, and social cacophony, and learning to live with CIPN. The 
awareness involved noticing symptoms, monitoring for changes, evaluating function, 
ignoring intense symptoms, and notifying the healthcare team of symptoms. Learning 
new lyrics symbolizes the difficulty patients had communicating the sensation of CIPN to 
the healthcare team so the symptoms could be understood. Role cacophony describes the 
interruption in activities of daily living, leisure, work, and role within the family. Some 
felt isolated when they could not participate in social activities. CIPN was also 
considered emotionally distressing. Learning to live with CIPN represents the trade-off 
for the benefit of treatment although the potential for irreversible nerve damage and 
permanent disability was of concern. Half of patients reported they had no recall of 
receiving education on CIPN. Patients reported healthcare providers assessed for CIPN, 
although rarely asked about the impact on daily living. Some received a change in 
chemotherapy or medications to control symptoms, while others ignored the symptoms 
and adjusted planned activities because of symptoms. The findings of this study 
contribute to the clarity of how those affected by CIPN live each day (Bakitas, 2007). 
Tofthagen (2010) describes the effects of CIPN and neuropathic pain in the lives 
of 14 patients with cancer. The sample consisted of 8 men and 6 women, ranging in age 
from 42-84 years. The cancer diagnoses of the participants included breast (28%), lung 
(28%), colorectal (22%), multiple myeloma (14%), and cholangeocarcinoma (7%). 
Participants received neurotoxic chemotherapy regimens containing paclitaxel (28%), 
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oxaliplatin (28%), docetaxel (22%), thalidomide (14%), or vinorebine (7%) and must 
have received these agents within three years of data collection. Semistructured 
interviews were conducted, recorded, and transcribed. The interviews ranged 10-45 
minutes in length, with participants being asked six questions related to CIPN symptoms; 
words to describe these symptoms; affect on daily life; interference with ability to 
function; what is most troubling about these symptoms; and participants were given 
opportunity to share any additional information about these symptoms. 
Participants reported a combination of sensory and motor symptoms associated 
with and without pain symptoms. The non-painful symptoms reported include numbness 
of fingers and toes (100%), loss of balance (57%), muscle weakness (57%), tingling 
(50%), generalized weakness (43%), lack of coordination (14%), short-term memory loss 
(14), trouble concentrating (14%), and loss of depth perception (7%). Almost 50% of 
patients reported near or actual injuries because of non-painful symptoms with 43% of 
participants reported being ambulatory prior to treatment who now require assistive 
devices to ambulate. Painful symptoms were reported including cold sensitivity (50%), 
pain (71%), burning (43%), muscle aches (36%), pins and needles (29%), soreness 
(22%), tremors (22%), jaw pain (14%), joint pain (14%), sharp pain (14%), shooting pain 
(14%), electric-like pain (7%), pressure (7%), stabbing pain (7%), and trampling pain 
(7%). Although patients had difficulty expressing or describing the painful sensation, the 
pain was located primarily in the upper and lower extremities. Neuropathic symptoms 
were described as interfering with usual activities such as activities of daily living (57%), 
walking (50%), picking up items (43%), driving (36%), hobbies (36%), relationships 
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(29%), household chores (22%), manual dexterity (22%), work (22%), writing (14%), 
exercise (7%), sexual activity (7%), and sleep (7%).  
The researcher reports patients had difficulty articulating symptoms of CIPN, 
which is consistent with the literature. The participants have been coping with 
neuropathic symptoms for up to three years and expressed their QOL had been adversely 
affected. The interference with ability to perform activities is a source of great emotional 
distress. This study supports the negative influences CIPN has on QOL, functional 
capacity, and emotion well being. 
Measurement Tools 
CIPN was once considered a minor problem that would resolve over time and 
seldom led to profound limitations (Smith, et al., 2008). This ideology has posed an 
important challenge to neuropathy measurement in the oncology setting. Commonly used 
grading scales, such as the National Cancer Institute Common Toxicity Criteria for 
Adverse Events (NCI-CTCAE) (National Cancer Institute, 2003), Eastern Cooperative 
Oncology Group (ECOG) (Oken, Creech, Tormey, Horton, Davis, McFadden, et al. 
1982),World Health Organization (WHO) (Miller, Hoogstraten, Staquet, & Winkler, 
1981), and Ajani (Ajani, Welch, Raber, Fields, & Krakoff, 1990) have different 
definitions of grade and do not define terms (Wilkes, 2007). This allows for subjective 
interpretation on behalf of healthcare providers leading to ambiguities when deciding 
treatment modifications based on current grading tools.  
An important study evaluating the inter-examiner and inter-test reliability 
between widely used grading scales was conducted by Postma, Heimans, Muller, 
Ossenkoppele, Vermorken, & Aaronson, (1998). Two neurologists independently rated 
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the severity of CIPN in 37 patients with 148 observations according to WHO, ECOG, 
Ajani, and NCI-CTCAE criteria. The majority of participants were female with ovarian 
cancer who had previously received paclitaxel and cisplatin.  The percentage of 
interobserver agreement on all grades of CIPN ranged from 46% to 84% (NCI-CTCAE 
46%, Ajani 57%, ECOG 76%, and WHO 84%). A comparison of the different grading 
scales showed the interobserver agreement utilizing grades 0 to 4 was the lowest using 
the NCI-CTCAE grading scale at 45.9% while the agreement on severe (grade 3) 
neuropathy using the NCI-CTCAE was 42% with 58% disagreement. The interobserver 
agreement between the ECOG grade 3 CIPN was 40% and 0% for the WHO and Ajani 
criteria. This study demonstrates clinicians interpret the evaluation criteria and grading 
for CIPN differently. The authors stated the differences occur when accounting for the 
interpretation of patient symptoms related to interference with function. These widely 
accepted grading tools do not incorporate patient’s subjective experiences of daily living 
and functional impairment in the scale parameters. These tools are useful for identifying 
patients who are need of neurological examination, however do not reflect the extent and 
severity of CIPN (Postma, et al., 1998). 
In an effort to quantify the symptoms and severity of CIPN, the Patient 
Neurotoxicity Questionnaire (PNQ) was developed by BioNumerik Pharmaceuticals with 
input from the Food and Drug Administration (FDA). It is a simple self-administered 
patient based questionnaire designed to delineate between interference and no 
interference in activities of daily living (ADL) resulting from CIPN (Hausheer, Schilsky, 
Bain, Berghorn, & Liberman, 2006). Shimozuma, Ohashi, Takechi, Morita, Ohsmi, 
Sunada, et al. (2004) evaluated the validity of this patient-based instrument with the 
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clinician-based instrument NCI-CTCAE and the Functional Assessment of Cancer 
Therapy-Taxane including neurotoxicity component (FACT/GOG-Ntx). The PNQ was 
utilized in a Phase III randomized trial comparing four treatment arms of different 
adjuvant taxane containing regimens in breast cancer patients in evaluating symptoms of 
neurotoxicity. CIPN symptoms were prospectively assessed in 300 patients at day thirty-
eight following surgery and at baseline, cycle three, cycle five, and cycle seven  of 
starting adjuvant therapy. The mean age was 51.7 years +/- 8.9, 55% had 1-3 positive 
nodes, 26.7% had.4-9 positive nodes, 18.3% had 10 or greater positive nodes. This study 
demonstrated that in a defined population of patients receiving neurotoxic chemotherapy, 
the PNQ is a reliable, sensitive, responsive instrument in the diagnosis and grading of 
CIPN with greater sensitivity than the FACT-Ntx and NCI-CTCAE. A lower incidence of 
severe forms of CIPN was reported by physicians based on the NCI-CTCAE as compared 
to the PNQ, thus demonstrating CIPN is under-reported by physicians. Kuroi et al. (2008) 
in a qualitative analysis evaluated the physicians’ perspectives regarding the utility and 
diagnostic value of the PNQ to assess CIPN. A questionnaire was sent to sixty-one 
physicians who participated in a Phase III randomized trial of adjuvant chemotherapy in 
breast cancer that used the PNQ to assess CIPN. Seventy-seven percent responded. The 
study concluded that neurosensory disturbances interfering with ADL are justification for 
treatment modifications. Based on the PNQ, moderate symptoms are justification for 
postponing treatment and severe symptoms should result in treatment discontinuation. 
Eighty-four percent reported the PNQ was helpful in the diagnosis and assessment of 
patients at risk for CIPN. The FDA has supported the use of the PNQ as a primary end 
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point in assessing the incidence and severity of CIPN in phase II and phase III trials in 
the United States (Hausheer, et al., 2006). 
Oncology nurses’ assessment is critical to early identification. Assessment of 
neurological function on a routine basis, monitoring those at risk is crucial to successful 
intervention. Smith et al (2008) reports the Total Neuropathy Score (TNS) developed for 
neurologist has been described as the most comprehensive tool available and should be 
considered for use by oncology nurses in evaluating for CIPN. This scoring system (0-32 
points) combines subjective sensory symptoms, subjective report of symptoms and 
amount of difficulty with daily activities, deep tendon reflex testing, manual muscle 
testing of muscles for the wrist and ankle, pin sensibility, quantitative vibration 
thresholds, and nerve conduction studies. This tool assesses neuropathy signs and 
symptoms and incorporates nerve conduction study results, but does not adequately 
assess painful neuropathy. The systematic review of seven studies describes the 
psychometric properties, clinical significance, and the utility of the TNS in assessing 
CIPN. This data synthesis concludes, this tool is too labor intensive for clinical practice, 
and inadequately assesses the pain component of neuropathy. This author also states, with 
basic physical assessment training and practice, nurses can become skilled at neuropathy 
assessment. 
Binner (2010) developed the Chemotherapy-Induced Peripheral Neuropathy: 
Assessment of Oncology Nurses’ Knowledge and Practice, a questionnaire to determine 
the knowledge oncology nurses have specific to CIPN and to evaluate practice behaviors 
and CIPN assessment skills. The questionnaire contains 16 knowledge items, 16 practice 
items, and 9 demographic items related to skills, instructions, and perceptions. The test 
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was administered to 39 oncology nurses in 2 outpatient infusion clinics. Test results were 
evaluated for reliability. 
This study indicated oncology nurses have adequate knowledge of CIPN with a 
mean knowledge score 12.6 (79%), out of a possible 16. All respondents indicated 
assessment of CIPN is essential to their role, 75% rated their CIPN assessment skills as 
fair to poor. Only 25% rated their assessment skills as good, and none rated their 
assessment skills as excellent. General physical assessment practices did not routinely 
include neurological physical assessment, 56.4% always or frequently perform baseline 
screening, 76.9 % always or frequently assess fine motor skills, 74.3% always or 
frequently document findings, 51.3% always or frequently assess risk factors, 76.9% 
always or frequently perform CIPN assessment prior to each infusion of a neurotoxic 
agent, 89.7% elicit symptoms of CIPN, 79.5% teach safety precautions. Oncology nurses 
reported never or occasionally performing deep tendon reflex testing (97.4%), muscle 
strength testing (77%), never or occasionally performing gross motor function testing 
(69.2%). The content validity index of this instrument was determined to be 0.95, and the 
internal consistency reliability was shown to be high, with a Cronbach’s alpha score of 
0.84. 
Prevention and Treatment Strategies 
Visovsky and colleagues (2007) constructed an evidenced based review of 
interventions aimed at the prevention and treatment of CIPN. The Oncology Nursing 
Society published this systematic review as a guide for oncology nursing practice. This 
analysis highlights a review of pharmacologic intervention studies utilizing amifostine, 
vitamin E, calcium and magnesium, nortriptyline, carbamazpine, acetyl-L-carnine, 
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glutamine, glutathione, alpha lipoic acid, and human leukemia factor for the prevention 
or reduction in CIPN. There is not enough evidence that meets the scientific rigor 
required to suggest any pharmacologic interventions for clinical practice. Non-
pharmacologic interventions such as acupuncture, assistive devices, pulsed infrared light 
therapy, transcutaneous nerve stimulation, capsaicin ointment, and spinal cord 
stimulation do not have established effectiveness in the prevention or treatment of CIPN. 
The studies evaluating the above non-pharmacologic interventions have limited or 
complete absence of data in the oncology population. 
Summary 
Chemotherapy induced peripheral neuropathy (CIPN) is an untoward side effect 
that can potentially adversely affect the quality of life of patients with cancer who receive 
neurotoxic chemotherapeutic agents. Oncology nurses face many challenges in providing 
comprehensive care to patients receiving cancer therapies that can result in CIPN. The 
literature supports a lack of a standard comprehensive, reliable, valid measurement tool 
that captures early symptoms of CIPN. Kuroi et al. (2008) reports the current tools do not 
consider the patients’ verbal reporting of symptoms of PN. The inability for patients to 
adequately articulate the symptoms of PN can be problematic for oncology practitioners 
in understanding the symptoms and the impact long term. The National Cancer Institute 
Common Toxicity Criteria for Adverse Events (CTCAE), World Health Organization 
(WHO), and Eastern Cooperative Oncology Group (ECOG) have different definitions of 
grade and do not define terms, which allows for subjective interpretation leading to 
ambiguities when deciding upon treatment modifications. 
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Visovsky et al. (2007) through the ONS Putting Evidence Into Practice (PEP) 
initiative provides a comprehensive review of the literature with no identified large, 
randomized, double-blind clinical trials showing pharmacologic and non-pharmacologic 
efficacy in the prevention and treatment of CIPN.  
Smith and colleagues (2008) reviewed the literature evaluating the usefulness of 
the Total Neuropathy Score (TNS) as an instrument designed to quantify CIPN that 
nurses may incorporate into clinical practice. It was determined this comprehensive tool 
assessing both subjective and objective aspects of peripheral nerve function lacked 
validity, adequate neuropathic pain assessment, and would require nurses to have basic 
knowledge of  physical neurological assessment. Binner (2010) developed the first tool to 
explore oncology nurses’ knowledge and practice behaviors specific to CIPN. This study 
concluded oncology nurses have adequate knowledge related to CIPN, CIPN assessment 
skills were rated as fair to poor by 75%, and assessment practices to not routinely include 
neurological physical assessment. This instrument was found to be valid and reliable with 
a Cronbach’s alpha score =0.84.This study is the only one to evaluate oncology nurses 
knowledge and practice behaviors. 
Bakitas (2007) evaluated 28 study participants in an attempt to clarify the CIPN 
symptom experience and the influence on everyday living. The metaphor of background 
noise was used to describe the constant drone of living with CIPN. Tofthagen (2010) 
purposely evaluated 14 oncology patients in a descriptive analysis examining the effects 
of CIPN and neuropathic pain. The participants described sensory and motor symptoms, 
with and without pain. The negative effects of CIPN on the physical and emotional 
wellbeing of patients with cancer are clearly described.  
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Chemotherapy induced peripheral neuropathy is a significant dose-limiting 
toxicity that adversely affects the lives of cancer patients. This symptom has been under-
reported, minimized by oncology practitioners, and inaccurately described as a minor 
problem. There are many gaps in the knowledge of standardized nursing assessment, 
interventions, and patient education in the literature. Oncology nurses need to be aware of 
the current state of the literature, and become knowledgeable of the distressing influence 
CIPN has on daily living. Nurses can advocate for patients by understanding the 
pathophysiology of CIPN, identifying risk factors, educating patients on early symptoms, 
collaborating with the healthcare team, and by anticipating the care the patient will 
require. This knowledge and empowerment may minimize, or alleviate the burden of 
CIPN. Nurses have great opportunity to evaluate their own gaps in knowledge of CIPN 
for the preservation of safety and improved quality of life of the oncology patient. 
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Chapter III: Methods 
This chapter outlines the research methods. Specifically the sample and setting, 
instrument, validity and reliability, consent process, and procedure for data collection and 
data synthesis are presented here. This project was a prospective, cross-sectional, 
descriptive study exploring oncology nurses’ knowledge, practice behaviors, and 
confidence in assessing CIPN. 
Sample 
This study was conducted at four Florida Oncology Nursing Society Chapter 
meetings located on the west and east coast and central Florida. The sample consisted of 
oncology nurses who are Oncology Nursing Society members and are chapter attendees. 
Study inclusion criteria supported participation from registered nurses who are currently 
providing or have in the past provided direct care to medical oncology-hematology 
patients and who can read, write, and speak English. Nurses whose oncology career has 
been outside of a medical oncology setting (i.e. critical care, surgical- oncology) were 
excluded.  
Instrumentation 
Chemotherapy-Induced Peripheral Neuropathy: Assessment of Oncology Nurses’ 
Knowledge and Practice-Revised. 
The Chemotherapy-Induced Peripheral Neuropathy (CIPN): Assessment of 
Oncology Nurses’ Knowledge and Practice-Revised instrument assesses the knowledge, 
practice behaviors and confidence oncology nurses have specific to CIPN (Appendix A) 
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(Binner, 2010). This instrument was selected because it is the only available tool 
evaluating nurses’ knowledge, practice behaviors, and confidence pertaining to CIPN. 
This questionnaire contains sixteen knowledge items, sixteen practice items, five 
confidence items, and nine-item demographic survey questions specific to skills, 
instruction, and perceptions. The CIPN knowledge questions score can range from 0-16 
based on number of correct answers. Unanswered questions are counted as incorrect. 
Practice domain questions are each rated to indicate frequency of practice behaviors on a 
scale of 0-3 (Never, occasionally, frequently, and always). The self-rated confidence 
questions are rated to indicate level of confidence in performing neurological physical 
assessment skills on a scale of 0-3 (Not at all confident, somewhat confident, confident, 
and very confident). These are not summed however, are reported as percentages (Binner, 
2010). 
Validity and Reliability 
To assess Content validity the Assessment of Oncology Nurses’ Knowledge and 
Practice-Revised instrument was evaluated by a panel of experts including two medical 
oncologist and three PhD prepared nurses who have published on CIPN. The instrument 
content-validity index was 0.95. Internal consistency reliability was evaluated using 
Cronbach’s alpha. The alpha coefficient for the entire instrument was 0.84 (Binner, 
2010).  
Procedures 
First, written permission to use the selected instrument was obtained from the 
author of the Chemotherapy-Induced Peripheral Neuropathy: Assessment of Oncology 
Nurses’ Knowledge and Practice-Revised instrument (Appendix B).Written permission 
 20
was then obtained from the Presidents of four Oncology Nursing Society (ONS) Chapters 
in Florida for the purpose of collecting data at their chapter meetings (Appendices C, D, 
E, & F). The Institutional Review Board (IRB) at the University of South Florida (USF) 
granted exempt status, so this study would be exempt from the process of signed consent 
(Appendix G). After study approval by the USF IRB, the CIPN: Assessment of Oncology 
Nurses’ Knowledge and Practice-Revised questionnaire was administered to a group of 
oncology nurses at the beginning of the Oncology Nursing Society (ONS) Chapter 
meeting held on the west coast, followed by an east coast chapter meeting, then a chapter 
meeting held in central Florida, with data collection ending at a meeting held on the west 
coast of Florida. The purpose of the study, study requirements, confidentiality, and 
voluntary participation were explained. Nurses were informed that by completing the 
questionnaire informed consent would be implied. All questions were answered to 
participants’ satisfaction. All data was kept anonymous and confidential. An assumption 
is that all oncology nurses have access to the literature regarding CIPN. 
Data Analysis 
Descriptive statistics were utilized to analyze the demographic data including 
frequencies and percentages, means, and standard deviations. Relationships between 
variables were assessed using the Pearson correlation coefficient. Data was analyzed 
using SPSS software version 16.0 to answer the research questions: Means and Standard 
deviations were utilized to answer research question one. Research questions two and 
three were addressed using frequencies and percentages. Pearson correlations were 
utilized to answer research question four. 
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Chapter IV: Results, Discussion, and Conclusions 
This chapter outlines the findings of this cross-sectional, descriptive study. The 
results, discussion, conclusions, and recommendations for future research are presented. 
Results 
Demographic Data 
The sample consisted of 70 oncology nurses, which included 69 females with 
demographic data missing on one participate. The age range of the participants was from 
26 to 68 years. The overall nursing experience, ranged from 1 to 47 years with experience 
specific to oncology nursing, ranging from 6 months to 32 years (Table 2).  
Table 2 
Mean and Standard Deviation of Demographic Variables for Participants 
Demographic Variable             Mean SD 
 
Age 
 
50.2 
 
  9.5 
 
Years in Nursing 
 
24.7 
 
12.2 
 
Years in Oncology 
 
13.5 
 
  7.4 
Note. Demographics (n=70, missing data on 1 participant). 
The participants varied in educational levels with both nursing education and 
highest education degree achieved examined (Table 3). In the nursing education category 
59 (74.3%) of the 70 participants had undergraduate degrees (Diploma, Associate of 
Science, or Bachelors of Science) while 10 (14.3%) had Masters of Science (9) or 
Doctoral (1) degrees. The highest education level achieved category was higher in 
Masters of Science (2.8%) and Doctoral degrees (1.5%) compared to nursing education 
 22
level category. Most were currently employed as registered nurses (85.7%) with a small 
subgroup (8.6%) employed as nurse practitioners. Among the participating oncology 
nurses, 65.7% held oncology certification. 
Table 3 
Frequency and Percent of Education and Clinical Characteristics 
Demographic Variable Response a Frequency Percent 
Generic Nursing Education Level           Diploma 
Associate 
Bachelors 
Masters 
Doctorate 
9 
21 
29 
9 
1 
12.9 
30.0 
41.4 
12.9 
  1.4 
Highest Attained Education Level Diploma 
Associate 
Bachelors 
Masters 
Doctorate 
7 
21 
28 
11 
2 
10.0 
30.0 
40.0 
15.7 
  2.9 
Current Position RN 
CNS 
NP 
Other 
60 
1 
6 
2 
85.7 
  1.4 
  8.6 
  2.9 
Oncology Nursing Certification No 
Yes 
23 
46 
32.9 
65.7 
Certification Type None 
OCN 
AOCNP 
OCCNS 
Other 
23 
40 
3 
0 
3 
35.7 
57.1 
  4.3 
     0 
  1.4 
Note. (n=69). aRN=Registered Nurse. CNS=Clinical Nurse Specialist. NP=Nurse 
Practitioner. OCN=Oncology Certified Nurse. AOCNP=Advanced Oncology Certified 
Nurse. OCCNS=Oncology Certified Clinical Nurse Specialist. 
 
 
 
 
 
 23
CIPN Knowledge 
The participant’s level of knowledge in non-pharmacologic management, 
pharmacologic agents, neuropathy terminology, assessment principals, and 
symptomatology specific to CIPN was assessed. The mean CIPN knowledge score was 
13.0 (SD=1.9) (81%) of 16.0 (Table 4). 
Table 4 
Mean and Standard Deviation of Knowledge Scores 
Variable Minimum Maximum Mean SD 
 
 
CIPN Knowledge 
 
8.0 
 
16.0 
 
13.0 
 
1.9 
Practice Behaviors 
Participants practice behaviors were assessed by self-reported evaluation of 
screening patterns, assessment skills, documentation, and patient teaching related to 
CIPN (Table 5). Screening for peripheral neuropathy prior to initiating the first dose of 
neurotoxic chemotherapy was always or frequently performed by 35, (50.0%) of 
participating oncology nurses. Evaluating patient’s fine motor skills was always or 
frequently done by 48 (68.6%) oncology nurses surveyed. Documentation of CIPN 
assessment findings was always or frequently documented by 45 (64.3%) nurses caring 
for this population of patients. Only 12 (17.2%) oncology nurses reported always or 
frequently assessing deep tendon reflexes. Muscle strength was always or frequently 
measured by only 25 (35.7%) oncology nurses. An assessment of other risk factors 
associated with peripheral neuropathy was always or frequently assessed among 39 
(55.7%) oncology nurses. Fine motor function such as evaluating gait, was always or 
frequently inspected by 37 (52.9%) oncology nurses surveyed. Of those surveyed, 41 
(58.6%) always, frequently incorporate CIPN assessment prior to each infusion of a 
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neurotoxic agent. Eliciting symptoms of CIPN from patients. was always or frequently 
done by 47 (65.7%) oncology nurses Teaching patient strategies for adapting to CIPN 
functional impairment was always or frequently taught by 40 (57.1%) of oncology 
nurses. Educating patients regarding safety precautions used to avoid injury, among those 
suffering from CIPN was always or frequently instilled by 52 (74.3%) oncology nurses 
who care for those affected by CIPN.  
Level of Confidence 
The level of self-confidence among the participants (n=70) in performing a 
neurological physical examination by assessing deep tendon reflexes, tuning fork 
vibration sensation, sharp vs. dull sensation, Romberg test, and manual muscle strength 
testing was evaluated (Table 6). The majority 50 (71.5%) of nurses reported a lack of 
confidence in assessing deep tendon reflexes, a lack of confidence in using a tuning fork 
to assess vibration sensation 51 (72.8%) and a lack of confidence in performing Romberg 
testing 51 (72.8%). Most, 62.8% reported being confident in performing the sharp vs. dull 
sensation assessment skill, and a reported 37 (52.9%) oncology nurses reported 
confidence in assessing manual muscle strength.  
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Table 5 
Frequency and Percent of Practice Behaviors 
Self-Reported Practice Behavior                                Response Frequency Percent 
Screen for baseline peripheral neuropathy                 Never 
Occasionally 
Frequently 
Always 
8 
27 
23 
12 
11.4 
38.6 
32.9 
17.1 
Assess fine motor skills  Never 
Occasionally 
Frequently 
Always 
10 
12 
37 
11 
14.3 
17.1 
52.9 
15.7 
Document CIPN assessment data Never 
Occasionally 
Frequently 
Always 
7 
18 
30 
15 
10.0 
25.7 
42.9 
21.4 
Assess deep tendon reflexes Never 
Occasionally 
Frequently 
Always 
38 
20 
9 
3 
54.3 
28.6 
12.9 
  4.3 
Assess muscle strength Never 
Occasionally 
Frequently 
Always 
17 
28 
20 
5 
24.3 
40.0 
28.6 
  7.1 
Assess for other risk factors associated with peripheral neuropathy Never 
Occasionally 
Frequently 
Always 
5 
26 
25 
14 
  7.1 
37.1 
35.7 
20.0 
Assess motor function skills (e.g., gait) Never 
Occasionally 
Frequently 
Always 
7 
26 
27 
10 
10.0 
37.1 
38.6 
14.3 
Perform CIPN assessment prior to each neurotoxic chemotherapy infusion Never 
Occasionally 
Frequently 
Always 
13 
16 
25 
16 
18.6 
22.9 
35.7 
22.9 
Elicit symptoms related to CIPN Never 
Occasionally 
Frequently 
Always 
6 
18 
36 
10 
 8.6 
25.7 
51.4 
14.3 
Teach patient strategies for adapting to CIPN functional impairment Never 
Occasionally 
Frequently 
Always 
10 
20 
35 
5 
14.3 
28.6 
50.0 
  7.1 
Teach safety precautions used to prevent injuries associated with CIPN 
(e.g., falls) 
Never 
Occasionally 
Frequently 
Always 
8 
10 
35 
17 
11.4 
14.3 
50.0 
24.3 
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Table 6 
Frequency and Percent of Confidence in Performing Neurological Physical 
Assessment Skills 
Assessment Skill Confidence Level 
Response 
Frequency Percent 
Deep tendon reflexes Not at all Confident    
Somewhat Confident 
Confident     
Very Confident 
23 
27 
17 
3 
32.9 
38.6 
24.3 
  4.3 
Tuning fork vibration 
sensation 
Not at all Confident    
Somewhat Confident 
Confident     
Very Confident 
29 
22 
15 
4 
41.4 
31.4 
21.4 
  5.7 
Sharp vs. dull sensation Not at all Confident    
Somewhat Confident 
Confident     
Very Confident 
9 
17 
32 
12 
12.9 
24.3 
45.7 
17.1 
Romberg test Not at all Confident    
Somewhat Confident 
Confident     
Very Confident 
36 
15 
13 
6 
51.4 
21.4 
18.6 
  8.6 
Manual muscle strength 
testing 
Not at all Confident    
Somewhat Confident 
Confident     
Very Confident 
11 
22 
24 
13 
15.7 
31.4 
34.3 
18.6 
 
Previous Education and Experience 
The participants’ previous education and experience obtained from demographic 
data was correlated with their knowledge pertaining to CIPN (n=69). Utilizing Pearson 
Correlation there was no significant relationship between generic nursing education level 
attained and knowledge of CIPN (r=.233, p=.054). There was however, a significant 
relationship between the highest education level achieved and CIPN knowledge  
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(r=.252, p=.037). Neither the number of years of experience in nursing nor the number of 
years of experience specific to oncology nursing were correlated with knowledge of 
CIPN. 
Discussion 
This study was initiated in recognition of the profound, negative effect CIPN has 
on the daily living of patients with varied cancer diagnoses and the lack of a standard 
approach among oncology nurses in addressing the care of patients who receive 
neurotoxic agents. This study may validate the existence of gaps in oncology nursing 
knowledge, practice behaviors and confidence pertaining to CIPN. These deficits, unless 
corrected, negatively influence patient outcomes, physical function, and enjoyment of life 
in those who are diagnosed with CIPN.  
Demographic Data 
Oncology registered nurses from ONS Chapter meetings across Florida 
participated in this prospective, cross-sectional descriptive study exploring oncology 
nurses’ knowledge, practice behaviors, and confidence in assessing CIPN. The 
participants consisted of registered nurses, nurse practitioners, a clinical nurse specialist, 
and nursing educators with the majority having undergraduate degrees. The sample was 
reflective of diverse oncology practice settings including inpatient hospital nurses, 
outpatient clinic nurses, and outpatient infusion nurses. The years of nursing experience 
and the years devoted specifically to oncology demonstrates participants are very 
experienced clinically and were very experienced in the care of the oncology patient. 
Most participants held oncology certification. A limitation of this prospective study is the 
relatively small sample size considering the number of eligible ONS members. Data were 
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not collected from a single site, but from several ONS chapters in different geographical 
regions throughout Florida. This makes the results from this study more generalizable. 
However, further study is needed in other states. Another study limitation was the 
potential for social desirability bias, whereby the participants may reply in a manner that 
is viewed as most favorable or correct. Further, nurses who choose to attend ONS 
meetings may be systematically different from other nurses who do not attend. 
CIPN Knowledge 
The mean CIPN knowledge score indicated adequate knowledge in the areas of 
non-pharmacologic management, pharmacologic agents, neuropathy terminology, 
assessment principals, and symptomatology specific to CIPN. Although the knowledge 
score is adequate, the scores range from 50%-100% (n=70) (Table 4). The initial cross-
sectional exploratory study piloting this questionnaire obtained similar results with a 
mean knowledge score 12.6 (79%) (1.7) indicating adequate nursing knowledge (Binner, 
2010). 
With the wide range in overall knowledge scores, this indicates there is a need for 
on-going education regarding the non-pharmacologic management, pharmacologic 
agents, neuropathy terminology, assessment principals, and symptomatology specific to 
CIPN among new oncology nurses and experienced oncology nurses alike. Education 
through continuing education programs, oncology nursing specific educational forums, 
college courses, and pharmaceutical industry initiated educational endeavors are 
necessary in providing oncology nurses’ with the knowledge necessary to care to patients 
receiving neurotoxic chemotherapeutic agents. 
 
 29
Practice Behaviors 
The practice behaviors subscales address screening, assessment skills, 
documentation, and teaching specific to CIPN (Table 5). Screening incorporates an 
assessment of baseline peripheral neuropathy symptoms prior to initiating the first dose 
of chemotherapy, assessment of other risk factors associated with peripheral neuropathy, 
and nursing assessment prior to each infusion of a neurotoxic agent. While the majority 
of the participants perform screening assessments prior to the first dose of chemotherapy, 
a significant number do not (Table 5). This data is consistent with the data reported by 
Binner (2010). 
Some conditions and co-morbidities can make patients more prone to developing 
the complication of CIPN. Cancer, autoimmune disorders, nutritional deficiencies, kidney 
disorders, vascular and metabolic disorders, infectious diseases, and hereditary disease 
can cause baseline peripheral neuropathy (Wickham, 2006). It is essential in oncology 
nursing practice to assess for risk factors to determine who may need closer monitoring 
for CIPN during treatment. Baseline neurological assessment and assessment prior to 
each dose of neurotoxic chemotherapy allows the nurse and healthcare team to recognize 
changes in peripheral neuropathy once therapy has begun. 
Assessment of CIPN incorporates fine motor skills, assessment of deep tendon 
reflexes, muscle strength, motor function skills, and eliciting symptoms related to CIPN. 
An assessment of motor, sensory, and autonomic function must be performed before, 
during, and after the completion of chemotherapy. An assessment specific to CIPN 
should include history, deep tendon reflexes, muscle strength, motor function, and an 
assessment of autonomic function (Armstrong, et al., 2005). Evaluating fine motor skills 
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by observing patients’ ability to grasp small objects or manipulate buttons on clothing 
can identify functional problems associated with CIPN (Armstrong, et al., 2005). Deep 
tendon reflex testing of the upper and lower extremities can provide information on the 
integrity of the peripheral nervous system with decreased reflexes indicate peripheral 
nervous system dysfunction. Muscle strength testing, noting weakness, and symmetry can 
provide information on the presence of motor fiber involvement by CIPN (Bickley, & 
Szilagyi, 2009). Assessing motor function by observing gait for unsteadiness, shuffling, 
wide base steps, or pain with ambulation may indicate CIPN (Armstrong, et al., 2005). 
Asking patients about the presence of CIPN may be as important as performing 
neurological testing (Rambaud, et al., 2001). 
The majority of oncology nurses reported incorporating assessment of fine motor 
and, gross motor function skills, and eliciting symptoms of CIPN routinely into practice 
while deep tendon reflex and muscle strength assessments are integrated with much less 
frequency. The ability to assess fine motor skills, elicit symptoms of CIPN, and motor 
function assessment may occur with greater frequency because of limited time required to 
assess for CIPN utilizing these assessment measures. This may also suggest greater 
confidence in interpreting the outcome of these functions with accuracy. Despite the 
increased frequency compared to other assessment skills, there remains a significant 
portion of nurses who do not incorporate these simple, although important, neurological 
assessments in their daily care of patients at risk for CIPN. Another consideration is 
oncology nurses may not be asking the proper questions to elicit symptoms related to 
CIPN. Muscle strength assessment and deep tendon reflex evaluation occurs with less 
frequency. This may indicate that these functions require a higher level of physical 
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assessment skill and may be perceived as the responsibility of the physician or nurse 
practitioner. These assessment skills also require time to perform, suggesting oncology 
nurses may not be working in an environment conducive to performing these skills on a 
routine basis due to time constraints. 
Binner (2010) found assessment of deep tendon reflexes, assessment of muscle 
strength, and assessment of motor function skills were incorporated into oncology 
nursing practice with much less frequency than assessment of fine motor skills and 
eliciting of CIPN symptoms. This difference between the two studies in frequency of 
assessing motor function skills may be related to a larger sample size, the diversity in 
clinical settings, and the influence of advance practice nurses included in the sample of 
the present study. 
Oncology nurses were asked to evaluate the frequency of documenting CIPN 
assessment data with the majority reportedly documenting assessment findings. A 
limitation of this study is elements of documentation pertaining to CIPN assessment and 
practice behaviors in oncology nursing practice are not included in this study. Further 
study is needed. The data supports that oncology nurses do not routinely incorporate 
screening, physical neurological assessment, or teaching related to adaptation and safety 
into practice. This suggests critical elements specific to CIPN are missing from the 
medical record. This creates a lack of continuity in patient care with an inability to follow 
improvement or progression of symptoms between treatment cycles. Binner (2010) 
reported consistent data. 
Teaching was assessed by evaluating the frequency of occurrence in educating 
patients on strategies for adapting to the functional impairment induced by CIPN and the 
 32
frequency of educating patients on safety precautions used to prevent injuries associated 
with CIPN. The majority of oncology nurses self-reported teaching patient strategies for 
adapting to CIPN functional impairment and educating patients regarding safety 
precautions used to avoid injury associated with CIPN. Binner (2010) obtained differing 
outcomes, the majority of oncology nurses reported never or occasionally teaching 
strategies for adaptation, while the majority always or frequently taught safety 
precautions. 
A significant number of oncology patients are not given strategies by their 
oncology nurse to adapt to the functional impairment. This may suggest oncology nurses 
feel helpless when functional deficits become evident. Safety precautions were not 
consistently addressed by approximately one-forth of the participants. This may reflect 
oncology nurses are unaware of how patients are forced to live or function at home with 
CIPN. There may also be a knowledge deficit on behalf of oncology nurses regarding the 
functional effects of CIPN by affected body location.  
Tofthagen (2010) suggests a multidisciplinary approach to CIPN. Open dialogue 
regarding the patients’ symptoms and performance status with the physician can ensure 
proper decisions are made regarding continued treatment utilizing the causative agent. 
Occupational therapy and physical therapy can have a vital role in assisting with 
maintaining functional capacity and evaluating safety needs. Identifying potential safety 
hazards in the home may help patients avoid injuries. Oncology nurses can provide 
anticipatory guidance in preparing patients for possible changes in physical, social, or 
emotional function. 
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Level of Confidence 
The level of self-confidence among the participants in performing a neurological 
physical examination by assessing deep tendon reflexes, tuning fork vibration sensation, 
sharp vs. dull sensation, Romberg test, and manual muscle strength testing was assessed 
(Table 6). The majority of participants reported greater confidence in performing sharp 
vs. dull sensation and manual muscle strength testing while having less confidence in 
assessing deep tendon reflexes, tuning fork vibration sensation testing, and Romberg 
testing. Sharp vs. dull sensation testing and manual muscle strength testing require only 
simple assessment tools for performing these functions. The lack of confidence in 
assessing deep tendon reflexes, tuning fork vibration and Romberg testing may indicate 
these skills requires a higher level of assessment knowledge in performing and there may 
be a knowledge deficit in interpreting the findings. Perhaps oncology nurses were never 
educated in performing these skills. These neurological assessment skills may be 
perceived as the responsibility of the physician or nurse practitioner. Binner (2010) did 
not report the level of confidence and perhaps this is an area for future exploration.  
Previous Education and Experience 
A significant, but weak relationship was identified between the highest 
educational level attained and CIPN knowledge, while no significant relationship was 
identified between nursing experience and knowledge of CIPN. The participants varied in 
their highest attained educational level; while most had Bachelor of Science degrees there 
were more Masters of Science and Doctoral degrees compared to basic nursing 
education. This relationship finding may represent a positive difference in higher 
education with specialized knowledge and oncology nurses’ ability to translate what is 
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learned into the clinical setting. Binner did not report on this relationship and may be an 
area of future exploration. 
Conclusions 
This is one of a few studies to document oncology nurses’ practice behaviors, and 
confidence, in addition to knowledge, and the relationship between education, 
experience, and knowledge of oncology nurses pertaining to CIPN. This study documents 
the current state of oncology nurses’ practice. The results support the need for enhancing 
the neurological assessment skills of oncology nurses. An efficient approach to CIPN 
assessment is needed to address the time constraints of the outpatient setting and the 
skillfulness required by oncology nurses in assessing for CIPN. The roles and 
responsibilities of assessing for CIPN should be delineated among oncology practices to 
overcome the ambiguity that currently exist among oncology nurses until evidence based 
CIPN assessment practice guidelines are developed. This study lays the foundation for 
future research and should serve as a stimulus for future studies. 
Recommendations for Future Research 
Oncology nurses desiring to capture a true reflection of assessment skills, practice 
behaviors, and patient outcomes related to CIPN have tremendous opportunity to 
contribute to the literature. A questionnaire examining the roles, responsibilities, 
perceptions, and barriers for healthcare providers in assessing and managing CIPN would 
provide further insight. Another area of exploration is a retrospective review of the 
medical record examining healthcare provider’s documentations of patients receiving 
neurotoxic agents. This would provide information into the assessment, and management 
of CIPN on behalf of nurses and physicians. Elements of patient descriptions of CIPN 
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could also be captured. This form of research would enable data collection and outcome 
measurement in a setting where no attempt is made to affect the outcome. Additional 
studies are needed to examine how patients live each day with CIPN, bringing attention 
and urgency to improving on our current practice and to the development of prevention 
and treatment strategies. Another area to explore where limited knowledge exists is the 
relationship between CIPN, interpersonal relationships, and sexual function. The piloting 
of a comprehensive CIPN patient assessment tool that is conducive to use in the current 
clinical environment is needed. Intervention studies are also needed to provide guidance 
on the prevention, and management of CIPN, and for the preservation of patient safety. 
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Appendix A 
 
 
CIPN: Assessment of Oncology Nurses’ Knowledge and Practice-Revised 
 
 
Multiple choices: Please check the best response. 
 
1. Nonpharmacologic strategies to consider in the management of symptoms associated with        
CIPN include all of the following except: 
Ο Use of assistive devices (e.g., cane, orthotic brace, splint 
Ο Use of heating pad 
Ο Transcutaneous nerve stimulations (TENS) 
Ο Acupuncture 
 
2.  Chemotherapy agents commonly associated with CIPN include: 
Ο Paclitaxel, Vincristine, and Doxorubicin 
Ο Paclitaxel, Cisplatin, and Gemcitabine 
Ο Cisplatin, Gemcitabine, and Doxorubicin 
Ο Paclitaxel, Cisplatin, and Vincristine 
 
3. An unpleasant, abnormal sensation is called: 
Ο Dystonia 
Ο Ataxia 
Ο Dysesthesia 
Ο Hyperreflexia 
 
 4. All of the following are part of the assessment of patients suspected of having CIPN except: 
Ο A test for impaired sense of balance 
Ο A test for deep tendon reflexes 
Ο Auscultation of lung sounds 
Ο Auscultation of bowel sounds 
 
5. A critical element in the clinical assessment of patients with CIPN is to: 
Ο Monitor vital signs during neurotoxic chemotherapy infusions  
Ο Determine the level of functional impairment involving ADLs  
Ο Evaluate patient’s orientation to time, place, and person  
Ο None of the above 
 
6. The essential first step in assessing CIPN is: 
Ο Sensory motor evaluation 
Ο Motor system evaluation 
Ο Patient interview 
Ο Autonomic system physical assessment 
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True/False: Check the correct response 
 
7. Orthostatic hypotension may indicate autonomic CIPN.  
Ο True                         Ο False      
8. Chemotherapeutic agents causing CIPN may affect position and vibration sense.  
Ο True                         Ο False    
9. Impaired proprioception may be a symptom of CIPN. 
Ο True                         Ο False 
10. The peripheral nervous system includes autonomic nerves. 
Ο True                         Ο False 
 
11. Sensory symptoms of CIPN typically progress in a proximal to distal pattern. 
Ο True                         Ο False    
 
12. The stocking-glove distribution of sensory symptoms of CIPN refers to the paresthesias in the        
hands and feet. 
Ο True                         Ο False       
 
13. Toxicity scales used to grade CIPN are very precise.   
Ο True                         Ο False    
 
14. Patients readily report symptoms of peripheral neuropathy.  
Ο True                      Ο False   
 
15. Oncology patients with diabetes or alcoholism are at greater risk for developing CIPN. 
Ο True                      Ο False   
 
16. Assessment of neuropathic pain requires a separate and unique approach compared   assessment 
of nociceptive (tissue) pain. 
Ο True                      Ο False 
 
How often do you do each of the following in your nursing practice? Check one for each 
question. 
 
17. How often do you screen patients for baseline presence of peripheral neuropathy prior to 
initiating the first dose of chemotherapy?  
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
18. How often do you assess patient’s ability to perform fine motor skills (e.g., button clothes, use 
of zippers) if they are receiving neurotoxic chemotherapeutic agents?   
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
19. How often do you document CIPN assessment data if the patient is receiving chemotherapy 
associated with CIPN? 
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
20. How often do you assess deep tendon reflexes on patients receiving neurotoxic chemotherapy? 
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
21. How often do you assess muscle strength in patients receiving neurotoxic chemotherapy? 
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
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22. How often do you assess patients for the presence of other risk factors associated with 
peripheral neuropathy? 
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
23. How often do you perform objective motor function assessment skills (e.g., muscle strength, 
gait assessment)?  
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
24. How often do you perform nursing assessment of CIPN prior to each infusion of neurotoxic   
chemotherapy?  
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
25. How often do you attempt to elicit patient symptoms related to chemotherapy-induced 
peripheral neuropathy? 
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
26. How often do you teach patients strategies for adapting to functional impairments secondary to 
CIPN?  
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
27. How often do you educate patients about safety precautions used to avoid injuries associated 
with CIPN (e.g., thermal injury, falls)? 
Ο Never                Ο Occasionally               Ο Frequently                Ο Always 
 
28. Check your level of confidence in performing each of the following physical assessment skills: 
 
a. Deep tendon reflexes 
Ο Not at all Confident      Ο Somewhat Confident      Ο Confident      Ο Very Confident 
 
b. Tuning fork vibration sensation 
Ο Not at all Confident      Ο Somewhat Confident      Ο Confident      Ο Very Confident 
 
c. Sharp vs. dull sensation 
Ο Not at all Confident      Ο Somewhat Confident      Ο Confident      Ο Very Confident 
 
d. Romberg test 
Ο Not at all Confident      Ο Somewhat Confident      Ο Confident      Ο Very Confident 
 
e. Manual muscle strength testing 
Ο Not at all Confident      Ο Somewhat Confident      Ο Confident      Ο Very Confident 
 
29. Is CIPN a significant problem for your patients receiving neurotoxic chemotherapy agents? 
Ο Yes                          Ο No 
 
30. Have you ever had instruction in assessment of CIPN? 
Ο Yes                          Ο No 
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31. Have you had instruction in physical assessment of CIPN in performing the following    
technique? 
a. Cranial nerves assessment     Ο Yes   Ο No 
b. Deep tendon reflexes             Ο Yes   Ο No 
c. Muscle strength                      Ο Yes   Ο No 
d. Orthostatic blood pressure     Ο Yes   Ο No 
e. Romberg test                          Ο Yes   Ο No 
f. Temperature sensation           Ο Yes    Ο No 
g. Dull/sharp sensation              Ο Yes    Ο No 
h. Vibration sensation                Ο Yes   Ο No 
 
32. Have you had instruction in: 
a. Pharmacology management of CIPN?                    Ο Yes           Ο No 
b. Non-pharmacologic management of CIPN?           Ο Yes           Ο No 
 
33. Do you believe assessment of CIPN is essential in your role as an oncology nurse? 
      Ο Yes           Ο No 
 
34. How would you rate the adequacy of your skill in assessing CIPN? (Check one) 
Ο Poor         Ο Fair         Ο Good           Ο Excellent     
 
35. Are patients routinely assessed for CIPN in your setting? 
      Ο Yes          Ο No  
 
36. If CIPN assessment is not routinely performed state reason. __________________________ 
 
Demographics 
 
37. Gender    Ο M      Ο F 
 
38. Age ___________ 
 
39. Years in Nursing ________ 
 
40. Years in oncology nursing __________ 
 
41. Generic Nursing Education (check highest level attained) 
Ο Diploma 
Ο Associate 
Ο Bachelors 
Ο Masters 
Ο Doctorate 
 
42. Education (check highest level attained)  
Ο Diploma 
Ο Associate 
Ο Bachelors 
Ο Masters 
Ο Doctorate     
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43. In your current position, are you a: (check one) 
      Ο RN         Ο CNS      Ο NP      Ο Other (please indicate) _____________ 
 
44. Do you have Oncology Nursing Certification? 
Ο Yes           Ο No 
 
45. If yes, please indicate which certification(s) you hold: 
      Ο OCN        Ο AOCNP      Ο OCCNS     Ο Other (please indicate) _____________ 
 
Additional Comments:   
 
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________ 
 
 
 
Thank You For Your Participation 
 
 
 
 
 
Chemotherapy-Induced Peripheral Neuropathy (CIPN): 
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Appendix B 
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